CN102341400A - 用作激酶抑制剂的吡咯并嘧啶化合物 - Google Patents

用作激酶抑制剂的吡咯并嘧啶化合物 Download PDF

Info

Publication number
CN102341400A
CN102341400A CN2010800108001A CN201080010800A CN102341400A CN 102341400 A CN102341400 A CN 102341400A CN 2010800108001 A CN2010800108001 A CN 2010800108001A CN 201080010800 A CN201080010800 A CN 201080010800A CN 102341400 A CN102341400 A CN 102341400A
Authority
CN
China
Prior art keywords
pyrrolo
pyrimidin
base
propyl group
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800108001A
Other languages
English (en)
Chinese (zh)
Inventor
E·G·姆西维尔
J·霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
Medical Research Council Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council Technology filed Critical Medical Research Council Technology
Publication of CN102341400A publication Critical patent/CN102341400A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010800108001A 2009-03-04 2010-03-04 用作激酶抑制剂的吡咯并嘧啶化合物 Pending CN102341400A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0903759.9A GB0903759D0 (en) 2009-03-04 2009-03-04 Compound
GB0903759.9 2009-03-04
US16203209P 2009-03-20 2009-03-20
US61/162,032 2009-03-20
PCT/GB2010/000394 WO2010100431A1 (en) 2009-03-04 2010-03-04 Pyrrolopyrimidines used as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102341400A true CN102341400A (zh) 2012-02-01

Family

ID=40580647

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800108001A Pending CN102341400A (zh) 2009-03-04 2010-03-04 用作激酶抑制剂的吡咯并嘧啶化合物

Country Status (8)

Country Link
US (1) US20120088753A1 (https=)
EP (1) EP2403853B1 (https=)
JP (1) JP2012519678A (https=)
CN (1) CN102341400A (https=)
AU (1) AU2010219466A1 (https=)
CA (1) CA2753236A1 (https=)
GB (1) GB0903759D0 (https=)
WO (1) WO2010100431A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093722A (zh) * 2012-02-09 2014-10-08 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
WO2015143692A1 (en) * 2014-03-28 2015-10-01 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN112225742A (zh) * 2020-12-11 2021-01-15 北京华氏开元医药科技有限公司 一种抑制vegfr活性的化合物、制备方法及应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
WO2012161877A1 (en) 2011-05-23 2012-11-29 Merck Patent Gmbh Pyridine-and pyrazine derivatives
BR112013029999B1 (pt) * 2011-05-23 2021-03-02 Merck Patent Gmbh derivados de tiazol, e medicamento
GB201114051D0 (en) 2011-08-15 2011-09-28 Domainex Ltd Compounds and their uses
DE102011112978A1 (de) 2011-09-09 2013-03-14 Merck Patent Gmbh Benzonitrilderivate
WO2013041605A1 (en) 2011-09-20 2013-03-28 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
DE102011119127A1 (de) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
NZ729618A (en) 2014-09-26 2018-07-27 Gilead Sciences Inc Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
AU2016219102B2 (en) * 2015-02-13 2020-10-15 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
KR101660863B1 (ko) 2015-04-03 2016-09-28 주식회사 녹십자 IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물
KR101846475B1 (ko) 2015-04-27 2018-04-09 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
EP3394044A1 (en) 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
DE102016113714A1 (de) 2016-07-26 2018-02-01 Rosa Karl Transfektionsverfahren mit nicht-viralen Genliefersystemen
WO2019156438A1 (en) 2018-02-07 2019-08-15 Korea Research Institute Of Chemical Technology Hetero ring-fused phenyl compounds for inhibiting tnik and medical uses thereof
KR102725207B1 (ko) 2018-02-07 2024-11-01 한국화학연구원 Tnik 저해용 화합물 및 이들의 의약 용도
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795556A1 (en) * 1996-02-29 1997-09-17 PHARMACIA & UPJOHN S.p.A. 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO2007024789A1 (en) 2005-08-24 2007-03-01 Lexicon Genetics Incorporated Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795556A1 (en) * 1996-02-29 1997-09-17 PHARMACIA & UPJOHN S.p.A. 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2007140222A2 (en) * 2006-05-26 2007-12-06 Novartis Ag Pyrrolopyrimidine compounds and their uses

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093722A (zh) * 2012-02-09 2014-10-08 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
CN104093722B (zh) * 2012-02-09 2016-07-27 默克专利股份公司 作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
WO2015143692A1 (en) * 2014-03-28 2015-10-01 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN112225742A (zh) * 2020-12-11 2021-01-15 北京华氏开元医药科技有限公司 一种抑制vegfr活性的化合物、制备方法及应用

Also Published As

Publication number Publication date
US20120088753A1 (en) 2012-04-12
WO2010100431A1 (en) 2010-09-10
EP2403853B1 (en) 2013-08-14
EP2403853A1 (en) 2012-01-11
GB0903759D0 (en) 2009-04-15
AU2010219466A1 (en) 2011-09-01
CA2753236A1 (en) 2010-09-10
JP2012519678A (ja) 2012-08-30

Similar Documents

Publication Publication Date Title
CN102341400A (zh) 用作激酶抑制剂的吡咯并嘧啶化合物
US20250026764A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
US7078410B2 (en) 2-arylamino-pyrimidines for the treatment of GSK3-related disorders
ES2338234T3 (es) Composiciones utiles como inhibidores de proteinas quinasas.
US8008481B2 (en) Indazole compounds
US6933294B2 (en) Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same
CN105452257B (zh) 新型稠合嘧啶化合物或其盐
US20100056524A1 (en) Compound
US20080039450A1 (en) Compounds
CN100463908C (zh) 取代的8’-吡啶基-二氢螺-[环烷基]-嘧啶并[1,2-a]嘧啶-6-酮和8’-嘧啶基-二氢螺-[环烷基]-嘧啶并[1,2-a]嘧啶-6-酮衍生物
CN102014914A (zh) 3h-[1,2,3]三唑并[4,5-d]嘧啶化合物、其作为mtor激酶和pi3激酶抑制剂的用途、以及它们的合成
US20180230152A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN101321756A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物
CN111406054A (zh) 作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物
CN107454902B (zh) 作为磷酸肌醇3-激酶抑制剂的色烯衍生物
CN111434662B (zh) 卤代烯丙基胺类化合物及其应用
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
CN102131806A (zh) 用作激酶抑制剂的三唑并吡啶化合物
CN108495855A (zh) 作为mnk抑制剂的稠合噻唑并嘧啶衍生物
US11744824B2 (en) 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds
WO2025218831A2 (zh) 具有ptpn2/ptpn1抑制活性的噻二唑烷酮衍生物及其制备方法和应用
CA2723745A1 (en) Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
US20240368104A1 (en) Novel Dialkoxynaphtho[2,3-C]Furan-1(3H)-One Derivatives and Pharmaceutical Composition For Preventing or Treating Respiratory Disease or SARS-COV-2 Infection Disease, Comprising Same
CN119604512A (zh) Tyk2抑制剂及其用途
CN118239953A (zh) 用于治疗PI3Kγ介导的疾病的化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120201